Cue Biopharma, Inc.
CUE
$30.50
$0.501.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -164.11M | -19.52M | -26.60M | -37.68M | -38.90M |
| Total Depreciation and Amortization | 2.40M | 2.47M | 2.00M | 853.00K | 839.00K |
| Total Amortization of Deferred Charges | 19.00K | 28.00K | 37.00K | 37.00K | 37.00K |
| Total Other Non-Cash Items | 109.83M | 4.42M | 6.17M | 6.88M | 7.26M |
| Change in Net Operating Assets | 1.81M | -11.85M | -3.30M | 272.00K | 2.62M |
| Cash from Operations | -50.05M | -24.46M | -21.69M | -29.64M | -28.14M |
| Capital Expenditure | -121.00K | -148.00K | -177.00K | -179.00K | -178.00K |
| Sale of Property, Plant, and Equipment | 40.00K | 40.00K | 40.00K | 21.00K | 98.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 212.00K | 212.00K | 212.00K | -6.79M | -- |
| Cash from Investing | 131.00K | 104.00K | 75.00K | -6.95M | -80.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.50M | -3.50M | -4.50M | -4.00M | -4.00M |
| Issuance of Common Stock | 14.77M | 13.05M | 12.75M | 1.82M | 11.64M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 27.55M | 18.05M | 18.05M | 18.05M | 18.05M |
| Cash from Financing | 39.82M | 27.60M | 26.29M | 15.87M | 25.69M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.10M | 3.24M | 4.68M | -20.72M | -2.54M |